Abstract
Background:
This study aimed to identify prognostic determinants in patients who underwent surgical management for endometrial carcinoma at a tertiary-level gynecological oncology center.
Materials and Methods:
A retrospective cohort analysis was performed, including patients who underwent primary surgical treatment for endometrial carcinoma between 2010 and 2025. Individuals with synchronous malignancies, incomplete follow-up data, prior neoadjuvant chemotherapy, or surgery performed at external institutions were excluded.
Results:
A total of 436 patients met the inclusion criteria. During follow-up, disease recurrence was observed in 58 patients, while 76 patients died. The overall survival (OS) rate was 82.6%, and recurrence-open-access survival (RFS) was 86.7%. Patients were stratified by the number of excised lymph nodes: ≤10 versus >10. RFS was 88.7% in the ≤10 group and OS was 84.6% in the >10 group (p = 0.432). No significant difference in recurrence rates was identified between the two groups (p = 0.201). While the extent of lymphadenectomy did not influence OS or RFS, lymph node metastasis was significantly associated with recurrence risk (odds ratios: 4.360, 95% confidence interval: 2.160–8.803, p < 0.001).
Conclusions:
The total number of lymph nodes removed did not significantly impact survival or recurrence rates. These findings highlight the growing importance of incorporating additional prognostic variables—such as molecular classifiers and lymphovascular space invasion—into individualized treatment planning and risk stratification in endometrial carcinoma.
Get full access to this article
View all access options for this article.